Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped

Data ReadoutnegativeDupixentNegative

AI Analysis

Summary

Sanofi's $1.4B acquisition of Kymab has faced another setback as atopic dermatitis trials were scrapped following therapy failure. This undermines Sanofi's strategy to replace revenue from Dupixent as it approaches patent expiration.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

atopic dermatitis trials scrapped; therapy failed to meet expectations

Importance:7/10

Sentiment:

-0.80

acquisitiontrial failureatopic dermatitispatent cliffpipeline setback

Related Companies

$SNY

Read the original article

Published by BioSpace on July 24, 2026 2:42 PM

Read Original